CORCEPT THERAPEUTICS INC Q3 FY2026 earnings call

• Endocrinology Division: Record revenue driven by increased awareness of hypercortisolism. Major clinical milestones include the American Diabetes Association and American Association of Clinical Endocrinology citing Catalyst study findings in their consensus reports, recommending screening for hypercortisolism in difficult-to-control diabetes patients.
• Oncology Division (Lifioly): Revenue grew 92% to $91.4 million. Over 1,700 physicians have prescribed Lifioly to more than 2,300 patients since its April launch. Rapid uptake is attributed to unique glucocorticoid receptor antagonism mechanism, immune system enhancement, and lack of required biomarker screening.
• Pipeline Updates: Relacorlin resubmission for Cushing syndrome is pending FDA decision by December 17 PDUFA date. BELLA trial results show significant benefit when combining Relacorlin with standard care earlier in treatment lines. MASH program (Miracoralin) showed dose-dependent liver fat reduction and fibrosis improvement in Phase IIb Monarch study. ALS program plans Phase III trial next year.

Total revenue for the third quarter of 2026 was $340.5 million, representing a 33% sequential increase and a 64% year-over-year growth. The Quorum and authorized generic segment contributed $249.1 million in revenue, accounting for approximately 73% of total sales. The LaFerriere (oncology) segment generated $91.4 million, contributing roughly 27% of total revenue. Net income stood at $126.8 million, up significantly from $43 million in the prior quarter.

• Management reiterated the full-year 2026 revenue guidance range of $1.1 billion to $1.2 billion.
• Guidance remains unchanged despite strong Q3 performance and growing contributions from both endocrinology and oncology segments.
• CFO noted that the midpoint represents best thinking and that guidance has been raised multiple times during the current fiscal year.

• Forward-looking statements are subject to risks described in SEC filings (Form 10-K and 10-Q), including uncertainties regarding clinical trial outcomes and regulatory approvals.
• Specific operational risks include potential liver injury signals associated with Relacorlin, which were addressed via additional statistical analysis requested by the FDA.
• Competitive landscape risks exist as new drugs enter the platinum-resistant ovarian cancer market, though management believes differentiated mechanisms protect market position.

Q: Analyst asked how new patient starts, treatment duration, and quarterly revenues relate as Lifioly matures, given rapid initial uptake.

A: Roberto Vieira explained that while initial patients had high unmet needs across multiple therapy lines, there is now growth in repeat prescribing and use in earlier lines of therapy. He expressed confidence in achieving market leadership and the previously discussed $1 billion revenue potential due to this expanding utilization pattern.

Q: Analyst questioned whether BELLA trial data showing greater benefit in earlier-stage disease changes Lifioly's positioning in treatment sequences.

A: Joe Belanoff confirmed that yes, they intend to move Lifioly earlier in the treatment path because cortisol modulation acts as a disease-modifying treatment. He emphasized that overall survival curves differ distinctly between arms, supporting earlier intervention, and noted expansion into other solid tumors expressing glucocorticoid receptors.

Q: Analyst asked why guidance was not raised despite strong Lifioly growth and good Coralline performance, inquiring about pent-up demand or price erosion assumptions.

A: CFO Atabak Mokari stated the guidance range reflects probabilistic best thinking and has already been increased several times this year. Joe Belanoff added that they do not see immediate negative impacts from emerging competitors like GenMab's RNA-S data, citing Lifioly's differentiated immune-modulating mechanism and combination potential as key differentiators.

Q: Analyst asked about FDA discussions ahead of the PDUFA date regarding labeling or liver injury signals, and details on Miracoralin dosing shifts in MASH.

A: Charlie Robb clarified that the FDA requested a specific global statistical test post-CRL, which yielded positive results leading to NDA resubmission; no further comments could be made before the decision. Bill Guyer explained the shift to 100mg daily Miracoralin aims to optimize efficacy based on dose-response data while minimizing ALT rises through an intermittent dosing schedule (3 weeks on, 1 week off).

Q: Analyst asked about balancing new diagnoses vs. switching patients from Corallum to Relacorlin upon launch, and titration/education processes.

A: Justin Gunn stated that while Relacorlin’s profile supports switching existing Corallum patients, the primary focus will be on treating the vast number of underserved, treatment-naive patients identified through Catalyst and Momentum studies, rather than focusing heavily on patient switching.